Shares of Bristol-Myers Squibb rose slightly while AstraZeneca declined amid reports of active deal talks between the two drugmakers.
Bristol-Myers Squibb and AstraZeneca remain in active merger discussions, following earlier reports of potential deal negotiations. The talks were confirmed in a recent update, though no formal agreement has been announced.
Bristol-Myers Squibb shares edged up 0.3% on the news, while AstraZeneca shares fell 1.2%. The discussions were previously reported by multiple outlets, indicating ongoing interest in a potential combination.
Market reaction has been muted, with limited movement in either stock beyond the initial response.